Bajaj Healthcare Announce New CDMO Agreement to Supply 15 APIs as Stocks Surge

• Bajaj Healthcare has entered into a definitive CDMO agreement with UK/EU based customers causing stocks to surge by 11%.

• The agreement involves the supply of 15 Active Pharmaceutical Ingredients (APIs). The APIs will be exclusively manufactured for its clientele at Savli Vadodara, Gujarat India.

Bajaj Healthcare has announced a definitive CDMO agreement with UK/EU based customers for the supply of 15 Active Pharmaceutical Ingredients (APIs).

Under this agreement, Bajaj Healthcare will undertake the development and supply of these molecules. These APIs encompass a diverse range of compounds, including off-patent generics and molecules soon to be off-patent. Shares of Bajaj Healthcare Ltd. gained as much as 11% after the announcement:

The CDMO agreement will be executed through its in-house R&D and manufacturing capacities at Savli Vadodara, Gujarat. This strategic location allows for efficient production and distribution, ensuring that the needs of their UK/EU customers are met promptly and effectively.

Anil Jain, Joint Managing Director, Bajaj Healthcare, commented on the business update, stating, “I am thrilled to share this strategic collaboration which underscores Bajaj Healthcare Ltd.’s commitment to innovation, excellence, and meeting the evolving needs of the pharmaceutical industry.”